• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Ascites and complications: getting to the root of the trouble.

作者信息

Mandorfer Mattias, Simbrunner Benedikt

机构信息

Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.

出版信息

Hepatobiliary Surg Nutr. 2023 Feb 28;12(1):124-127. doi: 10.21037/hbsn-22-625. Epub 2023 Jan 6.

DOI:10.21037/hbsn-22-625
PMID:36860249
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9944530/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1926/9944530/ac8f775aaaaf/hbsn-12-01-124-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1926/9944530/ac8f775aaaaf/hbsn-12-01-124-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1926/9944530/ac8f775aaaaf/hbsn-12-01-124-f1.jpg

相似文献

1
Ascites and complications: getting to the root of the trouble.腹水及其并发症：探寻问题根源
Hepatobiliary Surg Nutr. 2023 Feb 28;12(1):124-127. doi: 10.21037/hbsn-22-625. Epub 2023 Jan 6.
2
Transjugular intrahepatic portosystemic shunt in patients with cirrhosis: Indications and posttransjugular intrahepatic portosystemic shunt complications in 2020.经颈静脉肝内门体分流术治疗肝硬化患者：适应证和 2020 年经颈静脉肝内门体分流术相关并发症。
United European Gastroenterol J. 2021 Mar;9(2):203-208. doi: 10.1177/2050640620952637. Epub 2021 Feb 23.
3
Portal decompression by transjugular intrahepatic portosystemic shunt and changes in serum-ascites albumin gradient.经颈静脉肝内门体分流术进行门脉减压及血清腹水白蛋白梯度的变化
J Clin Gastroenterol. 1998 Sep;27(2):149-51. doi: 10.1097/00004836-199809000-00010.
4
Portal pressure gradient and serum albumin: A simple combined parameter associated with the appearance of ascites in decompensated cirrhosis treated with transjugular intrahepatic portosystemic shunt.门静脉压力梯度和血清白蛋白：与经颈静脉肝内门体分流术治疗失代偿性肝硬化腹水出现相关的简单联合参数。
Clin Mol Hepatol. 2019 Jun;25(2):210-217. doi: 10.3350/cmh.2018.0083. Epub 2019 Mar 22.
5
Transjugular intrahepatic portosystemic shunt in cirrhosis: An exhaustive critical update.肝硬化患者经颈静脉肝内门体分流术：详尽的批判性更新。
World J Gastroenterol. 2020 Oct 7;26(37):5561-5596. doi: 10.3748/wjg.v26.i37.5561.
6
Targeted puncture of left branch of intrahepatic portal vein in transjugular intrahepatic portosystemic shunt to reduce hepatic encephalopathy.经颈静脉肝内门体分流术时经皮穿刺左支门静脉以减少肝性脑病。
World J Gastroenterol. 2019 Mar 7;25(9):1088-1099. doi: 10.3748/wjg.v25.i9.1088.
7
Direct intrahepatic portocaval shunt (DIPS) or transjugular transcaval intrahepatic portosystemic shunt (TTIPS) to treat complications of portal hypertension: Indications, technique, and outcomes beyond Budd-Chiari syndrome.直接肝内门腔分流术（DIPS）或经颈静脉肝内门体分流术（TTIPS）治疗门脉高压并发症：布加综合征以外的适应证、技术和结果。
Clin Res Hepatol Gastroenterol. 2022 Apr;46(4):101858. doi: 10.1016/j.clinre.2022.101858. Epub 2022 Jan 7.
8
The role of transjugular intrahepatic portosystemic shunt in patients with portal hypertension: Advantages and pitfalls.经颈静脉肝内门体分流术在门静脉高压患者中的作用：优势与陷阱。
Clin Mol Hepatol. 2022 Apr;28(2):121-134. doi: 10.3350/cmh.2021.0239. Epub 2021 Sep 27.
9
Investigating the risk factors of hepatocellular carcinoma and survival analysis for cirrhosis after transjugular intrahepatic portosystemic shunt in treating portal hypertension.经颈静脉肝内门体分流术治疗门静脉高压后门静脉高压症患者肝细胞癌的危险因素及生存分析。
J Cancer Res Ther. 2018;14(4):826-832. doi: 10.4103/jcrt.JCRT_930_17.
10
Urinary aquaporin-2 excretion before and after transjugular intrahepatic portosystemic shunt insertion for refractory ascites.经颈静脉肝内门体分流术治疗顽固性腹水前后的尿水通道蛋白-2排泄情况
Scand J Gastroenterol. 2015 Apr;50(4):454-61. doi: 10.3109/00365521.2014.962610. Epub 2015 Jan 30.

引用本文的文献

1
Treating systemic inflammation by transjugular intrahepatic portosystemic shunt: Editorial on "Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis".经颈静脉肝内门体分流术治疗全身炎症：关于“经颈静脉肝内门体分流术置入可导致失代偿期肝硬化患者全身炎症持续逆转”的社论
Clin Mol Hepatol. 2025 Apr;31(2):615-619. doi: 10.3350/cmh.2024.1180. Epub 2025 Jan 6.

本文引用的文献

1
Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute-on-chronic liver failure.特利加压素在 1 型肝肾综合征和严重急性慢性肝衰竭患者中的应用与呼吸衰竭。
Aliment Pharmacol Ther. 2022 Oct;56(8):1284-1293. doi: 10.1111/apt.17195. Epub 2022 Aug 22.
2
Baveno VII - Renewing consensus in portal hypertension.《巴韦诺 VII 共识：门静脉高压领域的新共识》
J Hepatol. 2022 Apr;76(4):959-974. doi: 10.1016/j.jhep.2021.12.022. Epub 2021 Dec 30.
3
Recent advances in the understanding and management of hepatorenal syndrome.
肝肾综合征理解与管理的最新进展
Fac Rev. 2021 May 21;10:48. doi: 10.12703/r/10-48. eCollection 2021.
4
Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.腹水、自发性细菌性腹膜炎和肝肾综合征的诊断、评估及管理：美国肝病研究协会2021年实践指南
Hepatology. 2021 Aug;74(2):1014-1048. doi: 10.1002/hep.31884.
5
Prevention of First Decompensation in Advanced Chronic Liver Disease.预防晚期慢性肝病首次失代偿。
Clin Liver Dis. 2021 May;25(2):291-310. doi: 10.1016/j.cld.2021.01.003. Epub 2021 Mar 10.
6
Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome.特利加压素联合白蛋白治疗 1 型肝肾综合征。
N Engl J Med. 2021 Mar 4;384(9):818-828. doi: 10.1056/NEJMoa2008290.
7
Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality.在晚期慢性肝病的不同阶段，全身炎症反应增强，且与失代偿及死亡率相关。
J Hepatol. 2021 Apr;74(4):819-828. doi: 10.1016/j.jhep.2020.10.004. Epub 2020 Oct 16.
8
Where does TIPS fit in the management of patients with cirrhosis?经颈静脉肝内门体分流术（TIPS）在肝硬化患者的管理中处于什么地位？
JHEP Rep. 2020 May 23;2(4):100122. doi: 10.1016/j.jhepr.2020.100122. eCollection 2020 Aug.
9
Non-selective beta-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites.非选择性β受体阻滞剂会损害顽固性腹水肝硬化患者的整体循环稳态和肾功能。
J Hepatol. 2020 Dec;73(6):1404-1414. doi: 10.1016/j.jhep.2020.05.011. Epub 2020 May 21.
10
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.β 受体阻滞剂预防有临床显著门静脉高压症的肝硬化失代偿（PREDESCI）：一项随机、双盲、安慰剂对照、多中心试验。
Lancet. 2019 Apr 20;393(10181):1597-1608. doi: 10.1016/S0140-6736(18)31875-0. Epub 2019 Mar 22.